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Introduction: Many patients with endometriosis are treated with medication or by surgical approaches. However, a
small number of patients do not respond to medication and are inoperable because of comorbidities. This case
report shows the effectiveness of radiotherapy for refractory endometriosis and includes a time series of serum
estradiol levels.
Case presentation: A 47-year-old Asian woman presented to our facility with uncontrolled endometriosis
refractory to medication. Our patient was considered inoperable because of severe idiopathic thrombocytopenic
purpura, and underwent radiotherapy for massive genital bleeding requiring blood transfusions. A radiation dose of
20Gy in 10 fractions was delivered to the pelvis, including the bilateral ovaries, uterus, and myomas. An additional
10Gy in five fractions was delivered to the endometrium to control residual bleeding. Genital bleeding was
completely inhibited on day 46 after radiotherapy. Hormonal analysis revealed that radiotherapy induced
post-menopausal status. Two years after radiotherapy, atypical genital bleeding had not recurred and has been well
controlled without side effects.
Conclusions: Disrupted ovarian function is an adverse effect of radiotherapy. However, radiotherapy can be useful
for inducing menopause. In cases of medication-refractory or inoperable endometriosis, radiotherapy would be an
effective treatment option.
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Endometriosis is a gynecological condition characterized
by extra-uterine endometrial-like cells, which often pro-
liferate and cause hematomas, menstrual pain, or other
symptoms, in conjunction with hormonal changes.
In general, pain relievers and hormonal supplements
are prescribed during menopause [1-6]. However, when
endometriosis is refractory to medicinal treatments,
surgical intervention is required, including endometrial
tissue debridement or hysterectomy with/without ovar-
ian excision [7-10].* Correspondence: t.nomiya@med.id.yamagata-u.ac.jp
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reproduction in any medium, provided the orIn this study, we report the case of a patient with
refractory and inoperable endometriosis treated with
radiotherapy.Case presentation
A 47-year-old Asian woman presented to the Depart-
ment of Radiation Oncology, Yamagata University Hos-
pital, with a chief issue of massive atypical genital
bleeding.
Our patient was diagnosed as having idiopathic throm-
bocytopenic purpura (ITP) at three years of age; how-
ever, splenectomy, steroid therapy, and γ-globulin
therapy failed to improve her condition. She had severe
thrombocytopenia (platelet count <10,000 cells/mm3) at
the time of radiotherapy. Because of her history of ITP,
surgical intervention for endometriosis was ruled out.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pelvic magnetic resonance images of our patient before radiotherapy. (A) T1-weighted image; (B) T2-weighted image; (C) fat-
saturated T1-weighted image; (D) fat-saturated contrast-enhanced T1-weighted image. (a) Normal uterine body; (b) subserous myoma uteri; (c)
huge chocolate cysts (endometrial cysts) arising from the left ovary; (d) endometrial cysts arising from the right ovary.
Figure 2 Time course and amount of genital bleeding. The
amount of genital bleeding was scored by self-assessment from 0
(no bleeding) to 10 (the worst ever experienced). Before
radiotherapy, our patient experienced massive bleeding, requiring
daily transfusion of two to six units of packed red blood cells. The
amount of genital bleeding had reduced to half of the initial
amount at the end of radiotherapy. Thereafter, the amount of
bleeding continued to reduce and was completely inhibited by day
46. PRBC; packed red blood cells, RT; radiotherapy.
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bleeding for 10 years. She was diagnosed as having bilat-
eral ovarian chocolate cysts at the age of 40. Although
hormonal therapies (luteinizing-hormone-releasing hor-
mone (LH-RH) analog and contraceptive pills) were
administered, they were not effective, and medicinal
treatments were suspended without controlling the
symptoms. Our patient experienced massive genital
bleeding requiring daily transfusions of four to six units
of packed red blood cells (PRBCs) before radiotherapy
(Figure 1 shows the magnetic resonance images at that
time).
Bilateral ovaries (endometriotic cysts) were included as
radiotherapy targets to obtain radiation-induced meno-
pause. The uterine myoma and normal endometrium
were also included as targets as they may have been the
origins of genital bleeding. Radiotherapy of 20Gy in 10
fractions with 10MV photons was delivered to the tar-
gets, which was sufficient for inducing menopause. To
correct residual genital bleeding as per our patient's
wishes, another 10Gy radiation in five fractions was pro-
vided to the normal endometrium.
Figure 2 shows the time course and blood volumes of
the atypical genital bleeding. The first day of radiother-
apy was set as day 1, and the amount of bleeding per
day was assessed as often as possible. Because it is very
difficult to measure a precise volume of blood loss, a nu-
merical rating scale (NRS) from 0 (no bleeding) to 10
(excessive bleeding) was used along with self-assessment.Decreased bleeding occurred by day 14, and complete
arrest of bleeding was achieved by day 46. Following
treatment, no genital bleeding has been reported, and no
blood transfusion has been performed for two years after
radiotherapy.
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Before radiotherapy, her serum estradiol (E2) level was
161pg/mL (normal range; follicular phase: 19 to 226,
menopause: <39), serum follicle stimulating hormone
(FSH) level was 12.2mIU/mL (normal range; follicular
phase: 4 to 12, menopause: 39 to 176), and serum
luteinizing hormone (LH) level was 11.7mIU/mL (nor-
mal range; follicular phase: 1.1 to 8.1, menopause: 11 to
68.6). The serum E2 level rapidly decreased after the
start of radiotherapy and reached the post-menopausal
level two months later. At four months after radiother-
apy, the serum FSH level increased to 69.7mIU/mL
(post-menopausal level) and the serum LH level
increased to 29.2mIU/mL (post-menopausal level).
These serum hormone levels suggested that radiation-
induced menopause was successfully obtained two
months after the start of radiotherapy.
Discussion
Hormone therapies for endometriosis include medroxy-
progesterone, danazol, and gonadotropin-releasing hor-
mone (GnRH), among other drugs [1-3]. These drugs
have favorable effects for symptoms of endometriosis,
but they occasionally cause side effects such as spotting,
weight gain, skin changes, and hypo-estrogenism [4-6].
However, laparoscopic stripping of endometriomas is
reported to be as effective as surgical treatments [7].
Laparoscopic excision of the cyst wall of the endome-
trioma reduces the recurrence rates of endometriomas,Figure 3 Changes in serum hormonal levels from the onset of
radiotherapy. The serum estradiol level, which was very high
before radiotherapy, rapidly decreased after the onset of
radiotherapy (dashed line; pg/mL). The serum luteinizing hormone
level (solid line; mIU/mL) and serum follicle stimulating hormone
level (long dashed, short dashed line; mIU/mL) gradually increased
after radiotherapy. These changes in hormonal levels suggested that
our patient was of post-menopausal status. FSH; follicle stimulating
hormone, LH; luteinizing hormone, RT; radiotherapy.dysmenorrhea symptoms, non-menstrual pelvic pain,
and requirement for further surgery [8].
In our patient’s case, surgery could not be considered
as an option because our patient had underlying
thrombocytopenia (platelet count <10,000 cells/mm3)
due to ITP. Our patient seemed to have a very compli-
cated multiple disease scenario, with: (i) endometriosis
(bilateral ovaries), (ii) secondary chocolate cysts, (iii)
adenomyosis (complicating about 10% of the endometri-
osis), (iv) thrombocytopenia due to ITP and (v) uterine
myoma (subserous myoma). As it was considered that
all of the diseases might be a cause of bleeding, a par-
ticular state that ‘atypical bleeding gets worse according
to female hormone levels’ seemed to be mainly caused
by endometriosis. Therefore treatment was performed so
as to control the excess of female hormones. Treatment
to control the bleeding with interventional radiology
procedures was also considered, however, interventional
radiology procedures were not indicated because they
would not improve the essential cause of disease, there
was uncertainty of their effect and there was an inherent
risk associated with invasive procedures. Although oral
contraceptives and a GnRH analog were administered,
both drugs failed to suppress the endometriosis, and
only symptomatic treatments such as blood transfusion
were performed. Ectopic endometrial-like cell activity
is dependent on female hormone levels. Therefore,
anti-estrogen, androgen, and GnRH analog therapies
were implemented for symptomatic relief of the
endometriosis.
In our patient’s case, estrogen secretion was success-
fully inhibited by bilateral ovarian irradiation. A previous
study estimated that the 50% lethal dose (LD50) for
human oocytes was 4Gy or less [11]. Several studies
reported the ability of radiotherapy for ablating remnant
ovarian tissue in recurrent or refractory endometriosis,
based on the limited tolerance of human oocytes to radi-
ation damage [12-14]. These studies reported that meno-
pause was induced at a dose of 15 to 30Gy radiation. A
previous clinical study reported that menopausal status
had been obtained in almost all patients with breast can-
cer with distant metastases using a radiation dose of
10Gy in four fractions [15].
Radiotherapy is a less invasive treatment and is widely
applicable regardless of a patient’s age or operability.
Therefore, radiotherapy should be considered for
patients with medication-refractory and/or inoperable
endometriosis. However, one limitation of radiotherapy
is the irreversible loss of ovarian function; consequently,
careful consideration should be given to adolescents and
younger women who desire pregnancy. In our patient’s
case, radiotherapy was administered because our patient
did not desire ovarian preservation and because she was
at risk of life-threatening blood loss.
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We have demonstrated a case of refractory endometri-
osis successfully treated with radiotherapy and con-
clude that radiotherapy is an effective treatment
option for patients with medication-refractory or in-
operable endometriosis.
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